Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SNTI 
Senti Biosciences Inc (SNTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SNTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.5
1 Year Target Price $11.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -81.13% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.18M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 1 | Beta 2.14 | 52 Weeks Range 1.04 - 5.10 | Updated Date 01/10/2026 |
52 Weeks Range 1.04 - 5.10 | Updated Date 01/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -67.77% | Return on Equity (TTM) -394.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46272105 | Price to Sales(TTM) 55.46 |
Enterprise Value 46272105 | Price to Sales(TTM) 55.46 | ||
Enterprise Value to Revenue 134.22 | Enterprise Value to EBITDA -0.28 | Shares Outstanding 26290838 | Shares Floating 9706314 |
Shares Outstanding 26290838 | Shares Floating 9706314 | ||
Percent Insiders 56.75 | Percent Institutions 22.3 |
Upturn AI SWOT
Senti Biosciences Inc
Company Overview
History and Background
Senti Biosciences Inc. was founded in 2014 with the goal of developing novel cell therapies for cancer. The company has focused on engineering off-the-shelf cell therapies using its proprietary 'Sentelligent' gene circuit platform. Key milestones include securing significant funding rounds and advancing its lead product candidates into clinical trials. The company has evolved from a research-stage biotech to a clinical-stage biopharmaceutical company.
Core Business Areas
- Gene Circuit Engineering Platform: Development and application of proprietary gene circuits to control cell therapy behavior, enhancing specificity, efficacy, and safety. This platform allows for the creation of intelligent cell therapies that can sense and respond to their environment.
- Oncology Cell Therapies: Focus on developing genetically engineered cell therapies for various cancer indications. Their lead programs target solid tumors and hematological malignancies.
Leadership and Structure
Senti Biosciences Inc. is led by a management team with expertise in biotechnology, oncology, and gene therapy. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments dedicated to research and development, clinical operations, manufacturing, and corporate functions. Specific leadership roles such as CEO, CSO, and CFO would be detailed in their official corporate filings.
Top Products and Market Share
Key Offerings
- Competitors: CAR-T therapy developers (e.g., Gilead Sciences, Bristol Myers Squibb),Other CAR-NK therapy developers (e.g., Nkarta, Inc., Possessions Therapeutics)
- Market Share Data:
- Number of Users:
- Product Name 1: Senti-202 (AUTOTACu00ae Product Candidate) - A multi-specific off-the-shelf natural killer (NK) cell therapy designed to target and eliminate CD19-positive cancers, such as B-cell lymphomas and leukemias. Competitors include companies developing CAR-NK therapies and CAR-T therapies for similar indications.
- Revenue:
- Competitors: CAR-T therapy developers (e.g., Gilead Sciences, Bristol Myers Squibb),Other cell therapy developers targeting B-cell malignancies
- Market Share Data:
- Number of Users:
- Product Name 2: Senti-401 (AUTOTACu00ae Product Candidate) - A multi-specific off-the-shelf T cell therapy engineered to target and eliminate B-cell malignancies. Similar to Senti-202, it faces competition from established CAR-T therapies and emerging cell therapy approaches.
- Revenue:
Market Dynamics
Industry Overview
The cell therapy market, particularly for cancer treatments, is a rapidly growing and highly competitive field. It is characterized by significant scientific innovation, substantial investment, and a high rate of clinical trial activity. The focus is on developing more effective and safer therapies, with a trend towards allogeneic (off-the-shelf) approaches to overcome manufacturing and accessibility challenges of autologous therapies.
Positioning
Senti Biosciences Inc. is positioned as an innovator in the cell therapy space with its proprietary Sentelligent gene circuit platform, enabling the development of advanced, off-the-shelf cell therapies. Their strategy aims to address limitations of current cell therapies by engineering greater precision and control. Their competitive advantage lies in the modularity and programmability of their gene circuit technology.
Total Addressable Market (TAM)
The TAM for oncology cell therapies is substantial and projected to grow significantly, driven by increasing cancer incidence and the demand for novel treatment modalities. While specific TAM figures vary by indication, the global market for CAR-T and other cell therapies is estimated to be in the tens of billions of dollars. Senti Biosciences Inc. is positioned to capture a portion of this market by developing therapies for both hematological malignancies and solid tumors.
Upturn SWOT Analysis
Strengths
- Proprietary Sentelligent gene circuit platform enabling sophisticated cell therapy engineering.
- Focus on off-the-shelf (allogeneic) cell therapies, potentially improving scalability and accessibility.
- Experienced management team with a strong scientific background.
- Development of multi-specific therapies for broader target engagement.
Weaknesses
- Clinical-stage company with no approved products, hence no revenue generation from product sales.
- High burn rate typical of biotechnology companies engaged in extensive R&D and clinical trials.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Manufacturing complexity for advanced cell therapies.
Opportunities
- Expanding the application of their gene circuit platform to other diseases beyond oncology.
- Strategic partnerships and collaborations with larger pharmaceutical companies for development and commercialization.
- Addressing unmet needs in difficult-to-treat cancers.
- Advancements in gene editing and synthetic biology further enhancing their platform capabilities.
Threats
- Intense competition in the cell therapy and broader oncology market.
- Challenges in clinical trial success rates and potential for adverse events.
- Regulatory hurdles and evolving guidelines for cell therapy approvals.
- Patent challenges and intellectual property disputes.
- Financing risks and potential for dilution through future fundraising.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- Allogene Therapeutics (ALLO)
- Nkarta, Inc. (NKTX)
- Precision BioSciences, Inc. (DTIL)
Competitive Landscape
Senti Biosciences Inc. operates in a highly competitive landscape dominated by established pharmaceutical companies and well-funded biotechnology firms. Its competitive advantages lie in its novel gene circuit technology, which offers a unique approach to engineering cell therapies. However, it faces challenges in demonstrating clinical superiority and navigating the complex regulatory and manufacturing pathways compared to companies with approved products and established commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historically, Senti Biosciences Inc.'s growth has been characterized by the expansion of its research and development capabilities, the progression of its pipeline candidates through preclinical and early-stage clinical development, and the securing of significant funding to support these activities. Growth is measured by scientific advancements, team expansion, and the advancement of pipeline assets.
Future Projections: Future growth projections are heavily dependent on the successful outcomes of its ongoing and planned clinical trials, potential regulatory approvals, and the successful commercialization of its product candidates. Analyst estimates would typically focus on potential peak sales for its lead programs, but these are subject to significant uncertainty in the biotechnology sector.
Recent Initiatives: Recent initiatives would likely include the initiation of new clinical trials, strategic partnerships, advancements in manufacturing capabilities, and potential licensing agreements or collaborations to expand the reach of their platform and pipeline.
Summary
Senti Biosciences Inc. is a promising clinical-stage biotechnology company with a proprietary gene circuit platform for developing advanced cell therapies. Its strengths lie in its innovative technology and focus on off-the-shelf solutions. However, as a pre-revenue company, it faces significant risks related to clinical trial success, competition, and financing. Continued progress in clinical development and strategic partnerships will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Reputable financial news and data providers (e.g., Bloomberg, Refinitiv)
- Biotechnology industry research reports
- Company investor relations materials
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data for pre-revenue biotechnology companies can be highly volatile and subject to change. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senti Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2022-06-09 | Co-Founder, CEO & Director Dr. Timothy K. Lu M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sentibio.com |
Full time employees 34 | Website https://www.sentibio.com | ||
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.